The first telithromycin-resistant Streptococcus pneumoniae isolate in Japan associated with erm(B) and mutations in 23S rRNA and riboprotein L4

Japanese Journal of Infectious Diseases

Volumn 60, Issue 1, 2007, Pages 48-50

  Hirakata, Yoichi ^a   Mizuta, Yohei ^a   Wada, Akihito ^b   Kondoh, Akira ^a   Kurihara, Shintaro ^a   Izumikawa, Koichi ^a   Seki, Masafumi ^a   Yanagihara, Katsunori ^a   Miyazaki, Yoshitsugu ^a   Tomono, Kazunori ^a,c   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

23S RNA; BACTERIAL PROTEIN; CEFOTAXIME; CEFTRIAXONE; CLARITHROMYCIN; ERM B PROTEIN; ERYTHROMYCIN; IMIPENEM; LEVOFLOXACIN; PENICILLIN G; RIBOPROTEIN L4; RIBOSOME RNA; TELITHROMYCIN; UNCLASSIFIED DRUG;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BRONCHIECTASIS; CASE REPORT; DRUG EXPOSURE; FEMALE; HUMAN; JAPAN; LONG TERM CARE; MINIMUM INHIBITORY CONCENTRATION; NASOPHARYNX; NONHUMAN; NUCLEOTIDE SEQUENCE; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BRONCHIECTASIS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; JAPAN; KETOLIDES; METHYLTRANSFERASES; MIDDLE AGED; MUTATION; RIBOSOMAL PROTEINS; RNA, RIBOSOMAL, 23S; STREPTOCOCCUS PNEUMONIAE;

EID: 33947369340     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Felmingham, D., Reinert, R.R., Hirakata, Y., et al. (2002): Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J. Antimicrob. Chemother., 50 (Suppl. 1), 25-37.
2. Farrell, D.J. and Felmingham, D. (2004): Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003. Antimicrob. Agents Chemother., 48, 1882-1884.
3. Clinical and Laboratory Standards Institute (2006): Methods for dilution antimicrobial susceptibility testing for bacteria that grow aerobically; Approved standard. 7th ed. CLSI document M7-A7. Clinical and Laboratory Standards Institute, Wayne, Pa.
4. Clinical and Laboratory Standards Institute (2006): Performance standards for antimicrobial susceptibility testing; 16th informational supplement. CLSI document M100-S16. Clinical and Laboratory Standards Institute, Wayne, Pa.
5. Tait-Kamradt, A., Davies, T., Cronan, M., et al. (2000): Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob. Agents Chemother., 44, 2118-2125.
6. Hisanaga, T., Hoban, D.J. and Zhanel, G.G. (2005): Mechanisms of resistance to telithromycin in Streptococcus pneumoniae. J. Antimicrob. Chemother., 56, 447-450.
7. Canu, A., Malbruny, B., Coquemont, M., et al. (2002): Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother., 46, 125-131.
8. Walsh, F., Willcock, J. and Amyes, S. (2003): High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae. J. Antimicrob. Chemother., 52, 345-353.
9. Reinert, R.R., Wild, A., Appelbaum, P., et al. (2003): Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany. Antimicrob. Agents Chemother., 47, 2319-2322.
10. Davies, T.A., Dewasse, B.E., Jacobs, M.R., et al. (2000): In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother., 44, 414-417.
11. Rantala, M., Haanperä-Heikkinen, M., Lindgren, M., et al (2006): Streptococcus pneumoniae isolates resistant to telithromycin. Antimicrob. Agents Chemother., 50, 1855-1858.
12. Kudoh, S., Azuma, A., Yamamoto, M., et al. (1998): Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am. J. Respir. Crit. Care Med., 157, 1829-1832.